Antitussive Effects of the Leukotriene Receptor Antagonist Montelukast in Patients with Cough Variant Asthma and Atopic Cough

DOI Web Site Web Site PubMed 被引用文献6件 参考文献65件
  • Kita Toshiyuki
    Department of Respiratory Medicine, National Hospital Organization Kanazawa Medical Center
  • Fujimura Masaki
    Respiratory Medicine, Cellular Transplantation Biology, Kanazawa University Graduate School of Medicine
  • Ogawa Haruhiko
    Department of Respiratory Medicine, Ishikawa-Ken Saiseikai Hospital
  • Nakatsumi Yasuto
    Department of Respiratory Medicine, Kanazawa Municipal Hospital
  • Nomura Satoshi
    Department of Respiratory Medicine, Kanazawa Municipal Hospital
  • Ishiura Yoshihisa
    Department of Respiratory Medicine, Toyama City Hospital
  • Myou Shigeharu
    Respiratory Medicine, Cellular Transplantation Biology, Kanazawa University Graduate School of Medicine
  • Nakao Shinji
    Respiratory Medicine, Cellular Transplantation Biology, Kanazawa University Graduate School of Medicine

この論文をさがす

抄録

Background: Chronic cough is the only symptom of cough variant asthma (CVA) and atopic cough (AC). Cysteinyl leukotriene receptor antagonists have been shown to be effective in CVA, but there are no reports on their effectiveness in AC. To evaluate the antitussive effect of montelukast, a leukotriene receptor antagonist, in CVA and AC.<br> Methods: Seventy-five patients with chronic cough received diagnostic bronchodilator therapy with oral clenbuterol hydrochloride for 6 days. Of the 75 patients, 48 and 27 met the simplified diagnostic criteria for CVA and AC, respectively. Patients with CVA were randomly divided into 3 groups: montelukast, clenbuterol, and montelukast plus clenbuterol. Patients with AC were randomly divided into 2 groups: montelukast and placebo. The efficacy of cough treatment was assessed with a subjective cough symptom scale (0 meant "no cough" and 10 denoted "cough as bad as at first visit"). The cough scale, pulmonary function test, and peak expiratory flow rate (PEF) were evaluated before and after 2 weeks of treatment.<br> Results: In patients with CVA, 2-week treatment with montelukast, clenbuterol, and montelukast plus clenbuterol all significantly decreased cough scores and treatment with montelukast plus clenbuterol was superior to treatment with montelukast alone. In the montelukast plus clenbuterol group, PEF values in the morning and evening significantly increased after 2 weeks compared with values before treatment. In patients with AC, scores on the cough scale did not differ significantly between the montelukast group and the placebo group.<br> Conclusions: Montelukast was confirmed to suppress chronic non-productive cough in CVA, whereas it was not effective in non-productive cough in AC.<br>

収録刊行物

被引用文献 (6)*注記

もっと見る

参考文献 (65)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ